2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
10
Myelodysplastic Syndromes
4
Mycoses
4
Hematologic Neoplasms
4
Neoplasms
2
Leukemia
2
Brain Neoplasms
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neutropenia
1
Neoplasm, Residual
1
Myelodysplastic-Myeloproliferative Diseases
1
Mucormycosis
1
Leukemia, Myeloid
1
Invasive Fungal Infections
1
Glioma
1
Glioblastoma
1
Genetic Predisposition to Disease
1
Candidiasis
1
Bronchiolitis Obliterans Syndrome
1
Breast Neoplasms
1
Bone Marrow Neoplasms
1
Bone Marrow Failure Disorders
1
Aspergillosis
1
Anemia, Aplastic
1
Interventions
Trastuzumab
625
Paclitaxel
576
Cyclophosphamide
555
Docetaxel
484
Capecitabine
401
Letrozole
376
Fulvestrant
326
Doxorubicin
294
Carboplatin
279
Tamoxifen
275
Anastrozole
243
exemestane
228
Radiotherapy
218
Epirubicin
211
Bevacizumab
196
palbociclib
189
pertuzumab
184
Vinorelbine
167
Lapatinib
167
Gemcitabine
166
pembrolizumab
162
Surveys and Questionnaires
138
Exercise
136
Magnetic Resonance Spectroscopy
123
Fluorouracil
119
Blood Specimen Collection
118
eribulin
117
Albumin-Bound Paclitaxel
117
Drug Therapy
111
130-nm albumin-bound paclitaxel
111
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
posaconazole
×
Clear all
NCT06802757
2026-02-25
PRISM-TNBC
Shandong Cancer Hospital and Institute
Phase 2
Recruiting
72 enrolled